Hartmann´s Solution Fresenius Kabi

Hartmann's Solution Fresenius Kabi is an intravenous electrolyte solution containing potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate (as a 50 % solution). The product is supplied as a sterile solution for injection, with the exact concentration not publicly disclosed. It is classified as a prescription‑only IV fluid used to restore extracellular fluid volume and electrolyte balance in clinical settings across the EU healthcare environments.

Hartmann's Solution is indicated for situations where rapid fluid and electrolyte replacement is required, such as during surgery or acute dehydration. - Fluid resuscitation in patients with hypovolemia, hemorrhagic shock, or significant blood loss. - Electrolyte replacement to correct deficits of potassium, sodium, calcium, and lactate in acute settings. - Peri‑operative fluid management to maintain intravascular volume and hemodynamic stability during surgery. - Treatment of dehydration resulting from gastrointestinal losses, burns, or excessive sweating. - Support for patients on parenteral nutrition who require a balanced electrolyte composition.

Like all intravenous fluids, Hartmann's Solution may be associated with adverse reactions ranging from mild infusion‑site symptoms to rare but serious metabolic disturbances. Common: - Mild pain, burning, or irritation at the infusion site. - Transient increase in serum sodium or potassium levels. - Mild metabolic alkalosis due to lactate metabolism. - Slight elevation of blood calcium concentration. - Mild headache or dizziness during rapid infusion. - Temporary decrease in blood pressure (hypotension) if administered too quickly. Serious: - Hypernatremia or severe electrolyte imbalance. - Fluid overload leading to pulmonary edema. - Severe allergic or anaphylactic reaction. - Metabolic acidosis if lactate metabolism is impaired. - Severe hyperkalemia leading to cardiac arrhythmias. - Acute renal failure secondary to volume overload.

Clinicians should evaluate patient-specific factors before administering Hartmann's Solution to minimize risks and ensure appropriate fluid therapy. - Assess baseline electrolyte levels and renal function prior to infusion. - Adjust infusion rate in patients at risk for fluid overload or heart failure. - Use caution in individuals with severe liver disease due to altered lactate metabolism. - Avoid rapid administration in neonates and small children without weight‑based dosing. - Monitor blood pressure and cardiac rhythm during and after infusion. - Re‑evaluate serum electrolytes regularly during prolonged therapy.

Hartmann's Solution may interact with other intravenous or oral agents that affect fluid balance, electrolytes, or acid‑base status. Avoid: - Concurrent administration of hypertonic saline solutions, which can cause severe hypernatremia. - Simultaneous infusion of calcium‑containing medications through the same line without proper flushing. - Co‑administration with bicarbonate solutions, which may precipitate calcium carbonate and obstruct lines. Use with caution: - Loop diuretics, as they may exacerbate electrolyte shifts. - ACE inhibitors or ARBs, which can increase the risk of hyperkalemia. - Blood products, requiring careful monitoring of calcium and potassium levels. - Insulin therapy, which can alter potassium distribution when combined with the solution. - Vasopressors, because rapid volume expansion can potentiate blood pressure changes.